Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success

洛克菲勒大学临床和转化中心的总体愿景 科学（CCTS），由CTSA计划支持，是开发，演示和传播 创新项目，以创建一个建立在严谨基础上的模范临床研究企业， 负责任和透明的报告，以及科学诚信， 突破性的发现，改善人类健康。我们的新措施旨在：1） 确保我们所有的研究都设定了最高标准; 2）确保我们的学员拥有团队 科学领导技能需要在转化科学的职业生涯;和3）提高 科学严谨性、可重复性和报告性。这些新领域建立在 我们开发了基础设施，将机械科学融入社区参与， 接触基础科学家，加速健康促进产品的开发， 最佳的训练环境我们的具体目标是：1.提供强大的基础设施， 支持在最高水平的受试者安全性下开展临床研究， 科学严谨性、生物伦理学和法规遵从性。我们将加强我们的多学科 转化研究导航（TRN）计划以及我们与临床总监的合作 网络（CDN）是社区卫生中心基于实践的研究网络，以确保我们的 研究符合设计，可行性，方法有效性和透明度的最高标准 报告，支持我们积极参与CTSA试验创新网络。2.确保 洛克菲勒的每一项发现都有可能改善人类健康。我们将加强 我们强大的项目管道，以支持基础和临床研究人员将他们的 突破性的新疗法发现，通过利用 三机构治疗发展研究所，罗伯逊治疗发展基金， 和大学附属的生物技术公司，桥梁医药。教育整个 研究团队在最高级别的参与者中进行翻译研究 安全性、科学严谨性、生物伦理学和法规遵从性。我们会进一步加强 多学科团队科学强调我们的教育计划为KL 2临床学者， 临床研究护士，基础科学家和社区临床医生，重点是我们的新 团队科学领导力培训与CTSA中心在耶鲁大学， 宾夕法尼亚和哥伦比亚。4.研究和改进临床研究事业， 洛克菲勒和全国。我们将继续使用CCTS作为研究 临床研究企业本身及其改进方法，包括获得结果数据 从研究参与者，提高严谨性，可重复性和报告，加速评估 通过内部配方开发新疗法，并创建CTSA中心的“超级团队”， 传播我们的社区参与模式，利用基本的机制研究， 满足社区确定的卫生需求。我们将在整个CTSA中传播结果 通过出版物、演讲和积极参与， CLIC和CD 2 H倡议。

The overall vision of the Rockefeller University Center for Clinical and Translational Science (CCTS), supported by the CTSA program, is to develop, demonstrate, and disseminate innovative programs so as to create a model clinical research enterprise built on rigor, responsible and transparent reporting, and scientific integrity to empower translation of paradigm-breaking discoveries into better human health. Our new initiatives are designed to: 1) ensure that all of our studies set the highest standards; 2) ensure that our trainees have the team science leadership skills needed for a career in translational science; and 3) enhance scientific rigor, reproducibility, and reporting. These new areas build on the infrastructure we have developed to integrate mechanistic science into community engagement, reach out to basic scientists, speed the development of health- enhancing products, and create an optimal training environment. Our specific aims are: 1. To provide a robust infrastructure to support the conduct of clinical investigation at the highest levels of participant safety, scientific rigor, bioethics, and regulatory compliance. We will enhance our multidisciplinary Translational Research Navigation (TRN) Program and our collaboration with Clinical Directors Network (CDN), a Practice Based Research Network of Community Health Centers, to ensure that our studies meet the highest standards of design, feasibility, method validity, and transparent reporting, supporting our active participation in the CTSA Trial Innovation Network. 2. To ensure that every discovery at Rockefeller has the best chance of improving human health. We will enhance our robust pipeline of programs to support basic and clinical investigators move their paradigm-breaking discoveries into new therapeutics by leveraging the resources of the Tri-Institutional Therapeutic Development Institute, the Robertson Therapeutic Development Fund, and the University affiliated biotechnology company, Bridge Medicines .3. To educate the entire research workforce team in conducting translational research at the highest levels of participant safety, scientific rigor, bioethics, and regulatory compliance. We will further enhance the multidisciplinary team science emphasis of our educational programs for KL2 Clinical Scholars, Clinical Research Nurses, basic scientists, and community clinicians, with a focus on our new Team Science Leadership training with the CTSA Hubs at Yale, University of Pennsylvania, and Columbia. 4. To study and improve the clinical research enterprise both at Rockefeller and nationally. We will continue to use the CCTS as a laboratory for investigating the clinical research enterprise itself and methods to improve it, including obtaining outcome data from research participants, enhancing rigor, reproducibility and reporting, speeding the evaluation of novel therapeutics via in-house formulation, and creating 'super teams' of CTSA Hubs to disseminate our model of community engagement harnessing basic mechanistic studies to address community-identified health needs. We will disseminate the results throughout the CTSA consortium and scientific community by publications, presentations, and active participation in CLIC and CD2H initiatives.